Endocrine Abstracts

Background: Papillary thyroid carcinoma (PTC) is the most frequent subtype of thyroid cancers. Despite good prognosis in most cases, postsurgery recurrences and metastases can occur. Moreover, differential diagnosis between benign and malignant nodules is still challenging. Gaining knowledge about extracellular vesicles (EVs) in PTC could have a double benefit: a better understanding of PTC clinical behaviour, and the discovery of accessible (and accurate) diagnostic tools.</p...

Objectives: Hürthle cell (oncocytic) lesions can be metaplastic or neoplastic events. The neoplastic entities -formerly, oncocytic variant of follicular tumours; Hürthle cell neoplasm (HCN) - include HC adenomas and HC carcinomas and have been recognized as a separate class of tumours by the WHO. The remaining of the thyroid tumours demonstrating “mitochondrion-rich cells” and oncocytic morphology are referred under the umbrella term of “oncocytic vari...

Introduction and objectives: The cyclin-dependent kinases CDK4 and CDK6 are key regulators of the cell cycle entry, by phosphorylating the onco-suppressor retinoblastoma protein (pRb). CDK4/6 inhibitors (CDK4i) are already established as standard first-line treatment against advanced Estrogen Receptor-positive breast tumors, and have emerged as novel drugs to treat various pRb-proficient chemotherapy-resistant cancers. Presence of activating T172-phosphorylation of CDK4 in bre...

Objectives: RET fusion genes are known driver mutations in papillary thyroid carcinomas (PTCs) and have been described mainly in pediatric PTCs, in which they represent the most common genetic alteration. The aims of this study were to identify RET fusion genes in PTCs (from pediatric as well as adult patients), to correlate them with clinical and histopathological features and to determine the prognostic significance of RET fusion genes based on lon...

Objectives: BRAFV600E- anaplastic thyroid cancers (ATCs) show remarkable responses to dabrafenib and trametinib (dab/tram) an effect that may be in part immune-mediated. Murine BRAFV600E-ATCs regress upon BRAF inhibition. We find that recurrences are frequent and associated with loss of Mhc class II (MhcII) expression. Our goal was to investigate the mechanisms of loss of antigen presentation by tumor cells and whether this contributes to disease recurren...